Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIC-2201 in Relapsed/Refractory B Cell Malignancies
NCT06208735Phase 1Recruiting
- Sponsor
- BC Cancer
- Start
- Jan 2025
- Primary completion
- Aug 2027
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLIC-2201 in B cell lymphoma and B cell acute lymphoblastic leukemia (B-ALL), sponsored by BC Cancer. Primary endpoints: Maximum Tolerated Dose at 28 days, Cytokine Release Syndrome at 28 days and 4 more. Started Jan 2025; status: recruiting.
02
Drugs
CLIC-2201
03
Conditions
B cell lymphomaB cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06208735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208735.